Vivoryon Therapeutics AG successfully completes a 43 million Euro capital raise

Vivoryon Therapeutics AG announced in October 2019 that it has successfully raised capital of approximately 43 million Euro via a rights offering to existing shareholders and a private placement ­selected qualified investors in Europe. The proceeds from the offering will be used to fully finance the European Phase 2b clinical study with the Company’s lead product PQ912 for Alzheimer’s Disease, in particular for manufacturing the molecule PQ912 and testing it on approximately 250 patients. The announcement of the results is planned for 2022. The remaining proceeds will be used to prepare and initiate the US Phase 2b clinical trial with PQ912, and to expand Vivoryon’s drug portfolio into further therapeutic areas. The company based in Halle and the IZB in Martinsried has now left the IZB due to its growth strategy and is operating in Munich.


Dr. Michael Schaeffer, CBO,
Dr. Ulrich Dauer, CEO,
Vivoryon Therapeutics AG